Co-development
Joint programme with shared governance, milestones and negotiated IP allocation.
Typical horizon12–36 months
Corporate R&D
Research capacity you can contract, not hire.
Five engagement models connect corporate innovation mandates to validated laboratories, ICTs and scientific teams — with milestones, IP terms and incentive framing defined up front.
Engagement models
Choose the depth of collaboration.
White label innovation
Ready-to-brand formulations and technologies transferred under exclusivity windows.
Typical horizon6–18 months
Scientific validation
Independent testing of claims, mechanisms and performance for regulatory and marketing use.
Typical horizon3–9 months
Clinical studies
Protocol design, ethics approval, site management and statistical reporting.
Typical horizon9–30 months
Product development
From bench formulation to industrial specification, stability and packaging.
Typical horizon6–24 months
Technology transfer
Process package, training, validation batches and manufacturing qualification.
Typical horizon6–18 months
Innovation outsourcing
A managed external R&D function with dedicated teams, KPIs and tax-incentive capture.
Typical horizonRecurring
Open innovation
Active challenges seeking scientific answers.
New ingredients
Functional, bioactive and clean-label ingredients with validated mechanisms.
New technologies
Platforms at TRL 4–7 ready for corporate validation or licensing.
Researchers
Principal investigators matched by domain, method and publication record.
ICTs & universities
Accredited institutions for Art. 19 and 19-A structured partnerships.
Laboratories
Analytical, pilot and GxP-capable facilities with available capacity.
Specialists
Regulatory, clinical, IP and scale-up experts on demand.
Publications
Curated evidence base behind every asset and claim in the portfolio.